BioSpace News Archive

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2020. “Mustang had an eventful third quarter on the regulatory front, as the U.S.

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced a grant of stock options to a new employee to purchase 6,520 shares of the Company’s common stock with an exercise price of $14.75 per share, the closing price of Assembly’s common stock on November 2, 2020. The stock optio

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of November 2, 2020. The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The r

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 3, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 44,750 shares of Puma common stock to 5 new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the third quarter ended September 30, 2020. Financial results for the third quarter of 2020 Revenue for the third quarter of 2020 was $44,000, compared to $0.3 million for the third quarter of 20

Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced that its board of directors intends, subject to the receipt of stockholder approval of the Exchange (as defined below) and the reverse stock split, to declare a one-time special dividend on each outstanding share of Spring Bank’s common stock, payable

PDL BioPharma, Inc. (“PDL” or “the Company”) (Nasdaq: PDLI) announces it has rescheduled the date for announcing third quarter 2020 financial results and holding a conference call to Wednesday, November 11 , 2020. PDL will issue

Omnicell, Inc., a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced its participation in upcoming investor conferences

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) announced today that its management team will participate at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020. About Inari Medical, Inc. Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, n

ProPhase Labs Inc. has acquired a New Jersey laboratory owned by Confucius Plaza Medical Laboratory. Kennedy Capital served as the exclusive brokerage to the transaction. The lab, which is approved for a variety of medical tests, including Covid-19 and respiratory pathogen panel molecular tests, will be owned by the company’